LBH 589 + bortezomib + dexamethasone positive for Multiple Myeloma. Data published in Lancet Oncology- Novartis

Data published in The Lancet Oncology demonstrated a statistically significant and clinically relevant 4-month improvement in median progression-free survival (PFS) (hazard ratio=0.63 [95% confidence interval (CI): 0.52 to 0.76]; p<0.0001) for patients with relapsed or relapsed and refractory multiple myeloma when using the investigational compound lbh 589 (panobinostat) in combination with bortezomib and dexamethasone compared to placebo plus the same combination. in the phase iii panorama-1 (panobinostat oral in multiple myeloma) trial, the addition of lbh 589 also led to clinically meaningful increases in complete and near complete response rates and duration of response. the effect of lbh 589 was observed across all patient subgroups.>

See-

San-Miguel J, et al." Randomized Phase 3 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma."- The Lancet Oncology. 2014. Early Online Publication, 19 September 2014 doi:10.1016/S1470-2045(14)70440-1.